Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | HSPA1A | P0DMV8 | 1/20 | 0.39 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.39 |
| ▸ | CASP6 | P55212 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3382926 | 1.00 | KMT2A (0.56) | KMT2AMEN1SCN2AKEAP1CYP3A4 | |
| SCHEMBL3380658 | 1.00 | KMT2A (0.56) | KMT2AMEN1SCN2AKEAP1CYP3A4 | |
| SCHEMBL3379556 | 0.82 | KMT2A (0.39) | KMT2AMEN1SCN2AKEAP1CYP3A4 | |
| SCHEMBL3381978 | 0.82 | KMT2A (0.42) | KMT2AMEN1SCN2AKEAP1CYP3A4 | |
| SCHEMBL23043603 | 0.79 | POLB (0.53) | KMT2AMEN1KEAP1CASP6TDP1 | |
| SCHEMBL29978713 | 0.79 | POLB (0.53) | KMT2AMEN1KEAP1CASP6TDP1 | |
| SCHEMBL885606 | 0.79 | SCN2A (0.57) | KMT2AMEN1SCN2ACYP3A4NFKB1 | |
| SCHEMBL29395615 | 0.79 | SCN2A (0.57) | KMT2AMEN1SCN2ACYP3A4NFKB1 | |
| SCHEMBL3383759 | 0.78 | CASP6 (0.39) | KMT2AMEN1SCN2AKEAP1CYP3A4 | |
| SCHEMBL3383328 | 0.77 | S100A4 (0.37) | KMT2AMEN1SCN2AKEAP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280764-B1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2010-11-24 | — | — | EP | disclosed |
| US-20090181971-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. | 2009-07-16 | — | — | US | disclosed |
| US-7288567-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2007-10-30 | — | — | US | disclosed |
| EP-1524262-A1 | Inhibitors of histone deacetylase | Methylgene, Inc. (CA) | 2005-04-20 | — | — | EP | disclosed |
| EP-1280764-A2 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2003-02-05 | — | — | EP | disclosed |
| US-20020115826-A1 | Inhibitors of histone deacetylase | 92229129 QUEBEC INC. (CA) | 2002-08-22 | — | — | US | disclosed |
| WO-2001070675-A2 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE, INC. (CA) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115826-A1 | Inhibitors of histone deacetylase | HDAC1, HDAC5, HDAC3 | KMT2A 52/4885MEN1 2635/4885SCN2A 3707/4885 |
| US-20090181971-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC5, HDAC3 | KMT2A 52/4885MEN1 2635/4885SCN2A 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.